Cover Image
市場調查報告書

全球子宮內膜異位症市場

Global Endometriosis Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 274379
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
Back to Top
全球子宮內膜異位症市場 Global Endometriosis Market 2014-2018
出版日期: 2014年06月30日 內容資訊: 英文 79 Pages
簡介

全球子宮內膜異位症市場,預計從2013年到2018年,以2.86%的年複合成長率(CAGR)擴大。

本報告提供全球子宮內膜異位症市場趨勢與未來的成長預測、主要供應商的資訊等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品
    • 產品簡介

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 罹患率和得病率

第8章 各治療類型的市場區隔

  • 荷爾蒙治療
  • 止痛藥

第9章 各給藥途徑及劑型的市場區隔

  • 口服
  • 非口服
  • 局部

第10章 產品研發線

第11章 地理區分

第12章 購買標準

第13章 市場成長因素

第14章 成長因素與其影響

第15章 市場課題

第16章 成長因素與課題的影響

第17章 市場趨勢

第18章 趨勢與其影響

第19章 業者情勢

  • 競爭模式
    • 主要消息
  • 市場佔有率分析
  • 其他的供應商

第20章 主要供應商分析

  • AbbVie Inc.
  • AstraZeneca plc
  • Bayer AG
  • Pfizer Inc.

第21章 相關報告

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR3730

About Endometriosis

Endometriosis is a common female health condition where the endometrial tissue, which is usually found inside the lining of the uterus, appear and grows outside the uterine cavity. Endometriosis mostly occurs in the fallopian tubes, ovaries, outer surface of the uterus, pelvic cavity, vagina, cervix, and bladder. Endometriosis has rarely been reported in more distant parts of the body such as the lungs, brain, and skin. The most common symptoms associated with endometriosis are pelvic pain, dysmenorrhea, excessive bleeding, and lower abdominal pain. Some of the uncommon symptoms of endometriosis are rectal bleeding and hematuria. The detection of endometriosis in women is difficult because of the common symptoms associated with it. Endometriosis can be diagnosed by laparoscopy, ultrasound, pelvic exam, and biopsy of the inner lining of the uterus. In a biopsy, the tissues from the inner lining of the uterus of the patient are taken and tested using the biomarkers for the presence of endometriosis. Endometriosis is an incurable disease and relapses after the primary treatment. Currently, the treatment options for endometriosis include the usage of hormone therapy and analgesics to control the disease.

TechNavio's analysts forecast the Global Endometriosis market will grow at a CAGR of 2.86 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Endometriosis market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of endometriosis that are available in the market.

TechNavio's report, the Global Endometriosis Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC regions; it also covers the Global Endometriosis market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Abbvie Inc.
  • AstraZeneca plc
  • Bayer AG
  • Pfizer Inc.

Other Prominent Vendors

  • Astellas Pharma Inc.
  • Abbvie Inc.
  • Repros Therapeutics Inc.
  • Sanofi SA
  • Takeda Pharmaceuticals Co. Ltd.

Key Market Driver

  • High Unmet Needs in the Market

For a full, detailed list, view our report.

Key Market Challenge

  • Patent Expiries of Approved Drugs

For a full, detailed list, view our report.

Key Market Trend

  • Expected Launch of High-cost Therapies

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Rate of Incidence and Prevalence

08. Market Segmentation by Type of Therapy

  • 08.1.1. Hormone Therapy
  • 08.1.2. Analgesics

09. Market Segmentation by Route of Administration and Type of Dosage Form

  • 09.1.1. Oral
  • 09.1.2. Parenteral
  • 09.1.3. Topical

10. Pipeline Portfolio

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
  • 19.1.1. Key News
  • 19.2. Market Share Analysis 2013
  • 19.3. Other Vendors

20. Key Vendor Analysis

  • 20.1. AbbVie Inc.
    • 20.1.1. Key Facts
    • 20.1.2. Business Description
    • 20.1.3. Product Segmentation
    • 20.1.4. Revenue by Product Line
    • 20.1.5. Revenue Comparison 2012 and 2013
    • 20.1.6. Revenue by Geographical Segmentation
    • 20.1.7. Business Strategy
    • 20.1.8. Key Developments
    • 20.1.9. SWOT Analysis
    • 20.1.10. Strengths
    • 20.1.11. Weaknesses
    • 20.1.12. Opportunities
    • 20.1.13. Threats
  • 20.2. AstraZeneca plc
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Business Segmentation
    • 20.2.4. Business Strategy
    • 20.2.5. Revenue by Business Segmentation
    • 20.2.6. Revenue Comparison 2011-2013
    • 20.2.7. Sales by Geography
    • 20.2.8. Key Developments
    • 20.2.9. SWOT Analysis
    • 20.2.10. Strengths
    • 20.2.11. Weaknesses
    • 20.2.12. Opportunities
    • 20.2.13. Threats
  • 20.3. Bayer AG
    • 20.3.1. Key Facts
    • 20.3.2. Business Overview
    • 20.3.3. Business Segmentation
    • 20.3.4. Business Strategy
    • 20.3.5. Sales Segmentation by Business
    • 20.3.6. Sales by Geographical Segmentation
    • 20.3.7. Key Information
    • 20.3.8. SWOT Analysis
    • 20.3.9. Strengths
    • 20.3.10. Weaknesses
    • 20.3.11. Opportunities
    • 20.3.12. Threats
  • 20.4. Pfizer Inc.
    • 20.4.1. Key Facts
    • 20.4.2. Business Overview
    • 20.4.3. Business Segmentation by Revenue 2013
    • 20.4.4. Business Segmentation by Revenue 2012 and 2013
    • 20.4.5. Sales by Geography
    • 20.4.6. Business Strategy
    • 20.4.7. Key Developments
    • 20.4.8. SWOT Analysis
    • 20.4.9. Strengths
    • 20.4.10. Weaknesses
    • 20.4.11. Opportunities
    • 20.4.12. Threats

21. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Endometriosis Market 2013-2018 (US$ million)
  • Exhibit 3: Global Endometriosis Market by Type of Therapy
  • Exhibit 4: Global Endometriosis Market Segmentation by Type of Therapy 2013
  • Exhibit 5: Global Endometriosis Market by Route of Administration and Type of Dosage Form
  • Exhibit 6: Pipeline Portfolio of the Drugs for Endometriosis
  • Exhibit 7: Global Endometriosis Market by Geographical Segmentation 2013
  • Exhibit 8: AbbVie Inc.: Product Segmentation
  • Exhibit 9: AbbVie Inc.: Revenue by Product Line 2013
  • Exhibit 10: AbbVie Inc.: Revenue Comparison by Product Line 2012 and 2013 (US$ billion)
  • Exhibit 11: AbbVie Inc.: Revenue by Geographical Segmentation 2013
  • Exhibit 12: AstraZeneca plc: Business Segmentation
  • Exhibit 13: AstraZeneca plc: Business Segmentation by Revenue 2013
  • Exhibit 14: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ billion)
  • Exhibit 15: AstraZeneca plc: Sales by Geography 2013
  • Exhibit 16: Business Segmentation of Bayer AG 2013
  • Exhibit 17: Sales Comparison of Bayer AG by Business Segment 2012 and 2013 (US$ million)
  • Exhibit 18: Sales Segmentation of Bayer AG by Geography 2013
  • Exhibit 19: Pfizer Inc.: Business Segmentation by Revenue 2013
  • Exhibit 20: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 21: Pfizer Inc.: Sales by Geography 2013
Back to Top